(VIANEWS) – Chesapeake Energy Corporation (CHK), Catalyst Pharmaceuticals (CPRX), Merit Medical Systems (MMSI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Chesapeake Energy Corporation (CHK)
104.4% sales growth and 59.46% return on equity
Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. The company holds interests in natural gas resource plays, including the Marcellus in Northern Appalachian Basin in Pennsylvania; Haynesville located in Northwestern Louisiana; Eagle Ford in South Texas; Brazos Valley in Southeast Texas; and Powder River Basin in Wyoming. As of December 31, 2020, it owned interests in approximately 7,400 oil and natural gas wells, including 5,900 properties with working interest and 1,500 properties with royalty interest; and had estimated proved reserves of 60 Mmboe. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 59.46%.
Moving Average
Chesapeake Energy Corporation’s worth is way below its 50-day moving average of $90.18 and way under its 200-day moving average of $93.83.
Revenue Growth
Year-on-year quarterly revenue growth grew by 133.3%, now sitting on 13.59B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 25.1% and a drop 21.4% for the next.
2. Catalyst Pharmaceuticals (CPRX)
73.5% sales growth and 28.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.71.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 21.56. Meaning, the purchaser of the share is investing $21.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.55%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth is 51.6% for the present quarter and 73.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 59.2%, now sitting on 191.76M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 133.3% and 125%, respectively.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $15.31 at 05:22 EST, way under its 52-week high of $22.11 and way higher than its 52-week low of $6.15.
Previous days news about Catalyst Pharmaceuticals(CPRX)
- According to Zacks on Wednesday, 22 February, "Some better-ranked stocks in the drug sector include Catalyst Pharmaceuticals (CPRX Quick QuoteCPRX – Free Report) , Collegium Pharmaceutical (COLL Quick QuoteCOLL – Free Report) and Alaunos Therapeutics (TCRT Quick QuoteTCRT – Free Report) , While Catalyst Pharmaceuticals and Collegium Pharmaceutical sport a Zacks Rank of 1 (Strong Buy), Alaunos Therapeutics carries a Zacks Rank #2 (Buy). "
3. Merit Medical Systems (MMSI)
7.6% sales growth and 5.87% return on equity
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Earnings Per Share
As for profitability, Merit Medical Systems has a trailing twelve months EPS of $0.08.
PE Ratio
Merit Medical Systems has a trailing twelve months price to earnings ratio of 936.8. Meaning, the purchaser of the share is investing $936.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.87%.
Moving Average
Merit Medical Systems’s worth is below its 50-day moving average of $70.87 and way above its 200-day moving average of $62.42.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 1.14B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 5.6% and positive 9.4% for the next.
Volume
Today’s last reported volume for Merit Medical Systems is 67687 which is 73.9% below its average volume of 259424.
4. ShotSpotter (SSTI)
6.6% sales growth and 8.72% return on equity
ShotSpotter, Inc. provides precision-policing and security solutions for law enforcement and security personnel in the United States, South Africa, and the Bahamas. Its solutions include ShotSpotter Respond, a public safety solution, which serves cities and municipalities to identify, locate, and deter gun violence by incorporating a real-time gunshot detection system into their policing systems; and ShotSpotter Connect, a patrol management software to help plan directed patrols and tactics to deter a broad set of crime types. The company also provides ShotSpotter SecureCampus and ShotSpotter SiteSecure that helps the law enforcement and security personnel serving universities, corporate campuses, big-box retail, malls, and key infrastructure or transportation centers to mitigate risk and enhance security by notifying authorities of a outdoor gunfire incident and saving minutes for first responders to arrive. In addition, it offers ShotSpotter Investigate, a cloud-based investigative platform to help law enforcement agencies modernize every phase of an investigation and accelerate case work with easy-to-use software tools. Further, it provides ShotSpotter Labs, a technology to adapt and extend commercial technology to address significant wildlife and environmental issues. The company sells its solutions through its direct sales teams. ShotSpotter, Inc. was founded in 1996 and is headquartered in Fremont, California.
Earnings Per Share
As for profitability, ShotSpotter has a trailing twelve months EPS of $0.33.
PE Ratio
ShotSpotter has a trailing twelve months price to earnings ratio of 113.09. Meaning, the purchaser of the share is investing $113.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.72%.
5. AMETEK (AME)
5.3% sales growth and 16.16% return on equity
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices worldwide. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets. This segment also provides power quality monitoring and metering devices, uninterruptible power supplies, programmable power equipment, electromagnetic compatibility test equipment, gas turbines, and environmental health and safety market sensors, dashboard instruments for heavy trucks and other vehicles, and instrumentation and controls for the food and beverage industries; and aircraft and engine sensors, monitoring systems, power supplies, fuel and fluid measurement systems, and data acquisition systems for the aerospace industry. Its EMG segment offers engineered electrical connectors and electronics packaging to protect sensitive devices and mission-critical electronics; precision motion control products for data storage, medical devices, business equipment, automation, and other applications; high-purity powdered metals, strips and foils, specialty clad metals, and metal matrix composites; motor-blower systems and heat exchangers for use in thermal management, military, commercial aircraft, and military ground vehicles; and motors for use in commercial appliances, fitness equipment, food and beverage machines, hydraulic pumps, and industrial blowers. This segment also operates a network of aviation maintenance, repair, and overhaul facilities. In addition, the company offers clinical and educational communication solutions. AMETEK, Inc. was founded in 1930 and is headquartered in Berwyn, Pennsylvania.
Earnings Per Share
As for profitability, AMETEK has a trailing twelve months EPS of $3.77.
PE Ratio
AMETEK has a trailing twelve months price to earnings ratio of 37.42. Meaning, the purchaser of the share is investing $37.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.16%.
